Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Murielle Roussel, Benjamin Hébraud, Cyrille Hulin, Aurore Perrot, Denis Caillot, Anne‐Marie Stoppa, Margaret Macro, Martine Escoffre, Bertrand Arnulf, Karim Belhadj, Lionel Karlin, Laurent Garderet, Thierry Façon, Shien Guo, Josh Weng, Sujith Dhanasiri, Xavier Leleu, Philippe Moreau, Michel Attal
Abstract
< .001). Similarly, both groups showed clinically meaningful improvements from baseline in fatigue, pain, and disease symptom scores. Side effects of treatment scores remained stable. In the RVd-ASCT group, there was transient worsening in HRQoL immediately after ASCT. These findings suggest that the clinical improvements observed with RVd-based treatment are accompanied by overall improvements in HRQoL for patients with NDMM.
Topics & Concepts
LenalidomideMedicineMultiple myelomaDexamethasoneBortezomibQuality of life (healthcare)Internal medicineMaintenance therapyMelphalanAutologous stem-cell transplantationOncologyClinical trialPhysical therapySurgeryChemotherapyNursingMultiple Myeloma Research and TreatmentsCancer Treatment and PharmacologyHistone Deacetylase Inhibitors Research